been a longstanding challenge in medicine, because BT information can be exploited to maximize potency and minimize toxicity during drug administration and thus will enable highly optimized medication. To address this challenge, we previously developed the concept, ''molecular-timetable method,'' which was originally inspired by Linné 's flower clock. In Linné 's flower clock, one can estimate the time of the day by watching the opening and closing pattern of various flowers. Similarly, in the molecular-timetable method, one can measure the BT of the day by profiling the up and down patterns of substances in the molecular timetable. To make this method clinically feasible, we now performed blood metabolome analysis and here report the successful quantification of hundreds of clock-controlled metabolites in mouse plasma. Based on circadian blood metabolomics, we can detect individual BT under various conditions, demonstrating its robustness against genetic background, sex, age, and feeding differences. The power of this method is also demonstrated by the sensitive and accurate detection of circadian rhythm disorder in jet-lagged mice. These results suggest the potential for metabolomics-based detection of BT (''metabolite-timetable method''), which will lead to the realization of chronotherapy and personalized medicine.
I n the 18th century, the Swedish botanist Karl von Linné designed a ''flower clock'' comprising a series of plant species arranged according to the respective time of the day their flowers open or close. Watching this flower clock, one can estimate the time of the day by noting the pattern of flower opening and closing. Since Linné's early times, it has been a well known fact that plants have an internal clock and thereby can open or close their flowers at a precise time of the day. Similarly, animals possess an internal molecular mechanism, a ''circadian clock,'' which underlies endogenous, self-sustained oscillations with a period of Ϸ24 h manifest in diverse physiological and metabolic processes (1) . In mammals, several clock genes, including Clock, Bmal1, Per1, Per2, Cry1, Cry2, RevErbA, Rora, Csnk1e, Csnk1d, and Fbxl3, regulate, at least in part, gene expression in central and/or peripheral clock tissues (2) (3) (4) . Reflecting the temporal changes in gene expression in central and peripheral clock tissues (5) (6) (7) (8) , the potency and/or toxicity of administered drugs depend on the individual's present body time (BT) (9) (10) (11) (12) (13) . It has been suggested that administrating a drug at a specific BT improves the outcome of pharmacotherapy by maximizing its potency and minimizing its toxicity (14) . In contrast, administrating a drug at an inappropriate BT can result in severe side effects (15) . Despite the importance of such BT-dependent therapy (also known as ''chronotherapy'') (9) (10) (11) (12) (13) , its application to clinical practice has been obstructed by a lack of clinically feasible methods for measuring BT.
To overcome this problem, we previously developed the concept of a ''molecular-timetable method (16) ,'' which was originally inspired by Linné's flower clock. In Linné's flower clock, one can estimate the time of the day by watching the opening and closing pattern of various flowers. Similarly, in molecular-timetable method, one can measure the BT of the day by profiling the up and down pattern of substances in the molecular timetable. This concept was proven using the expression profile of clock-controlled genes in a target organ (16) . However, estimates of BT from the expression profile of oscillating substances within a target organ (in this case, the liver) are hard to apply directly to clinical situations. To make the molecular-timetable method more clinically relevant, we decided to determine BT from blood samples, which are more available in clinical practice.
In the blood of mammals, several small chemical substances such as metabolites and hormones have been reported to exhibit circadian oscillations. For example, the concentration of the steroid hormone, corticosterone, is rhythmically controlled by circadian clock with a peak in the evening (17) , and an amine-derived hormone, melatonin, show circadian rhythm with a peak in the early morning in mice (18) . In humans, several peptide hormone levels show daily variations; growth hormone increases during sleep (19) , leptin increases during the evening (20) , and prolactin increases at night (21) . Concentrations of amino acids, including tryptophan, tyrosine, phenylalanine (22) , methionine (23) , cysteine, glutathione (24), and homocysteine (25), also exhibit daily variations in human blood plasma. Despite these findings, comprehensive profiling of circadian dynamics of chemical substances in mammalian blood has not yet been reported, and until now a comprehensive molecular timetable of such chemical substances has not been constructed.
Metabolomics technology aims to comprehensively identify and/or quantify the dynamic chemical substances present in biological samples. It is gaining interest in the fields of drug discovery, disease diagnostics, and treatment (26-28). The present metabolomics technology was developed rapidly by coupling advanced separation technology with highly sensitive and selective mass spectrometry-gas chromatography mass spectrometry (GC/MS) (29-31), liquid chromatography mass spectrometry (LC-MS) (32-34), and capillary electrophoresis mass spectrometry (CE-MS) (35, 36) . To construct the molecular timetable from clinically available samples, we have performed blood metabolome analysis in this study. Using the LC-MS technique, we quantified hundreds of clock-controlled metabolites in mouse plasma and successfully constructed a molecular timetable of blood metabolites. This metabolite timetable allowed us to measure individual BT under various conditions and was robust enough to be used in mice with different genetic backgrounds, sex, age, and feeding conditions. It was also sensitive and accurate enough to detect circadian rhythm disorders in jet-lagged mice. Our preliminary results suggest that other metabolomics techniques such as CE-MS can also be applied to the molecular-timetable method, demonstrated by the quantification of hundreds of clock-controlled metabolites, the identification of substantial portion of these metabolites, and successful measurement of BT from independent blood samples. Thus, metabolomics-based measurement of BT will contribute to the potential areas of chronotherapy and personalized medication regimens.
in the molecular peak time), are high, whereas those of duskindicating metabolites, which peak at approximately ZT12 or CT12 (Fig. 1B , red color bars in the molecular peak time), are low. Conversely, at ZT12 or CT12, concentrations of dawn-indicating metabolites are low, whereas those of dusk-indicating metabolites are high; this suggests that time-indicating metabolites can represent BT (BT), the endogenous state of circadian clock. In fact, the oscillations of these time-indicating metabolites are directly or indirectly controlled by circadian clock, because the disruption of functional molecular clock in Cry1Ϫ/Ϫ, Cry2Ϫ/Ϫ mice (37) results in the alteration of circadian oscillations of these metabolites (Fig.  S1 ). We used these LC-MS data to construct the molecular timetable of time-indicating metabolites (a ''metabolite timetable'') in mouse plasma (Table S1 online). We also note that, among these time-indicating metabolites (i.e., oscillatory peaks detected by LC-MS), 14 oscillatory peaks were identified as various types of lysophosphatidylcholines with different unsaturated fatty acids ( Fig. 1 C and D) . Measurement of BT from Independent Samples. To verify whether the metabolite timetable was a good indicator of BT, we attempted to estimate the BT from the metabolite profiles of independently sampled mice. We collected fresh blood plasma from individual young male CBA/N mice every 4 h over 24 h under both LD or DD conditions because of the possibility that sampling time and/or light conditions would affect the accuracy of BT estimation. LC-MS analysis was performed to profile the time-indicating metabolites in the plasma samples ( Fig. 2 A and B) . After measured profile of the time-indicating metabolites was normalized by using the metabolite timetable, we filtered out outliers, fitted the normalized profile to cosine curve, and calculated the significance of its fitness (see also Materials and Methods) . This metabolite-timetable method could successfully detect significant circadian rhythmicity in all metabolite profiles of these samples (P Ͻ 0.01, Fig. 2 A and B) . . On the heat maps, magenta tiles indicate a high quantity of substances and green tiles indicate a low quantity in plasma. Metabolites are sorted according to their molecular peak time (molecular peak times are indicated as colors). (C and D) Identified oscillatory peaks measured by negative ion mode (C) and positive ion mode (D). Mean value was set to 1.0. tion errors of 1.0 Ϯ 0.49 h for LD and 1.3 Ϯ 0.45 h for DD (mean Ϯ SD, Table S2 ). Estimation error was here defined as time difference between estimated BT and sampling time (environmental time). These results suggest that BT can be accurately determined from the metabolite profiles of independently sampled mice.
Differences in Genetic Backgrounds. In clinical situations, methods for BT detection must apply to populations with heterogeneous genetic backgrounds. To demonstrate the suitability of the metabolite-timetable method for individuals with different genetic backgrounds, we applied the method to other inbred mouse strain with genetic backgrounds that differed from the original CBA/N strain. We chose C57BL/6, because C57BL/6 and CBA/N are genetically remote from each other and classified into 2 completely different clusters among 55 mice strains according to SNP-based study (38). We collected the blood plasma samples from individual young male C57BL/6 mice every 4 h over 24 h under LD and DD conditions and quantified the time-indicating metabolites in the plasma by LC-MS ( Fig. 3 A and B) . The metabolite-timetable method detected significant circadian rhythmicity (P Ͻ 0.01) in all metabolite profiles both under LD ( Fig. 3A ) and DD conditions ( Fig. 3B ) even if we used the metabolite timetable constructed from CBA/N mice. The estimated BT closely matched with the environmental time with the estimation errors of 1.6 Ϯ 0.36 h for LD and 1.7 Ϯ 0.24 h for DD (mean Ϯ SD, Table S2 ). These results suggest that BT can be accurately determined from the metabolite profiles of mice with heterogeneous genetic backgrounds.
Differences in Age and Sex. We constructed the metabolite timetable from young male mice only, so it was possible that age and sex factors might affect the accuracy of the metabolite-timetable method. To determine the influence of age and sex, we also applied the metabolite-timetable method to aged male and young female mice of the same strain. Blood plasma from individual aged male or young female CBA/N mice was sampled at 2 time points, ZT0 (the beginning of the day, i.e., time of light on) and ZT12 (the end of the day, i.e., time of the light off) under LD condition. These time points were considered as 2 ''noisiest'' time points, because light conditions were dramatically changed at these points. Timeindicating metabolites in the plasma were quantified by LC-MS ( Fig. 4A ) and significant circadian rhythmicity (P Ͻ 0.01) was detected in all metabolite profiles of both the aged male mice and the young female CBA/N mice (Fig. 4A ). The estimated BT from individual mice sampled at ZT0 and ZT12 were BT23.0 and BT11.0 in aged male mice and BT1.2 and BT13.2 in young female mice (Table S2 ). These results demonstrate that BT can be accurately determined from the metabolite profiles of mice of different age and sex.
Differences in Feeding Conditions. The circadian rhythmicity of food intake is well known (39); therefore, feeding conditions may severely affect the accuracy of the metabolite-timetable method. To validate the use of the metabolite timetable in individuals with different feeding conditions, we applied the metabolite-timetable method to CBA/N mice deprived of food (food deprivation). This feeding condition differed greatly from the original feeding condition where CBA/N mice were allowed ad lib feeding. We collected the blood plasma from individual young, male, food-deprived CBA/N mice every 4 hours over 24 h under LD condition. LC-MS analysis was performed to quantify the plasma metabolites (Fig.  4B ). The metabolite-timetable method detected significant circadian rhythmicity (P Ͻ 0.03) in all metabolite profiles. The estimated BT matched with the environmental time with the estimation errors of 2.2 Ϯ 0.50 h (mean Ϯ SD, Table S2 ). These results suggest that BT can be determined from the metabolite profiles of mice even under severe feeding conditions. (Table S1 ). The red cosine curve is the estimation, the blue curve is the environmental time (pre LD condition shift), and the brown cosine curve is the environmental time (post shift). See also Table S2 for statistics. of 3.5 h from the original LD cycle, indicating incomplete entrainment to the advanced cycle, i.e., jet lag ( Fig. 5C and Table S2 ). These results suggest that the metabolite-timetable method can accurately detect circadian rhythm disorders. Another set of BT estimation data for jet-lagged mice supports this conclusion ( Fig. S2 and Table S2 ). S3A ). We used these CE-MS data to construct the metabolite timetable in mouse plasma (Table S3 ). Notably, 28 peaks (18.3% of the total) were identified as known metabolites ( Fig. S3B ).
To confirm whether the CE-MS-based metabolite timetable was a good indicator of an individual's BT, we estimated BT from the metabolite profiles of independently sampled mice. Fresh plasma from young male CBA/N mice was collected every 4 hours over 24 h both under LD and DD conditions. CE-MS analysis was performed to profile the time-indicating metabolites ( Fig. S3 C and D) . The CE-MS-based metabolite-timetable method detected significant circadian rhythmicity in all metabolite profiles of these samples (P Ͻ 0.01, Fig. S3 C and D). The estimated BT was close to the environmental time with estimation errors of 0.6 Ϯ 0.29 h for LD and 0.6 Ϯ 0.54 h for DD (mean Ϯ SD, Table S4 ). These results suggest the metabolite-timetable method is generally applicable to other metabolomics technologies such as CE-MS. See Fig. S3 E-H and SI Text for the result at a more stringent criterion (FDR Ͻ 0.01).
Discussion
We identified 14 and 28 oscillatory peaks in mouse blood as known metabolites in LC-MS and CE-MS analysis, respectively. For example, a different type of lysophsophatidylcolines exhibit significant circadian oscillations in LC-MS analysis ( Fig. 1 C and D) . The genes for key enzymes synthesizing lysophosphatidylcoline are Lcat (lecitine:cholesterol acyltransferase), Lipc (hepatic lipase), and Lipg (endothelial lipase). Among these genes, Lcat and Lipc are mainly expressed in liver. We found that Lipc mRNA are rhythmically expressed in the mouse liver with the peak time around peak time (PT) 5 (8) , which slightly proceeds with the peak time of identified oscillatory lysophosphatidylcolines (PT5.8-9.1). In CE-MS analysis, many amino acids exhibit significant circadian rhythmicity. For example, glutamine (Gln), threonine (Thr), proline (Pro), valine (Val), phenylalanine (Phe), methionine (Met), isoleucine (Ile), leucine (Leu), and tryptophan (Trp) peak at around midnight (ϷPT18), whereas glycine (Gly) peaks in the evening (PT12.1) ( Fig.  S4 ). In the urea cycle, metabolites such as ornithine (PT18.6), citrulline (PT19.9), and 4-guanidino-butyrate (PT20.1) exhibit significant circadian rhythmicity (FDR Ͻ0.1). Arginine (Arg), which plays an important role in the urea cycle, also exhibits suggestive circadian rhythmicity (FDR ϭ 0.215; PT0.6) in our CE-MS data. It is also noteworthy that the final product-Urea-is reported to vary over 24 h in the blood of certain species such as rabbits (41) and rats (42). Interestingly, Reddy et al. (43) showed that 3 key enzymes involved in the urea cycle, carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase 1 (ASS1), and arginase 1 (ARG1), show circadian rhythms in the liver, the center of the urea cycle and urea formation (43). In the creatine pathway and neighboring glycine and threonine metabolism, metabolites such as guanidoacetate (PT6.2), Creatine (PT14.7), creatinine (PT18.7), sarcosine (PT18.0), and dimethylglycine (PT16.5) exhibit significant circadian rhythmicity (FDR Ͻ0.1). Arginine (PT0.6) first converts to guanidoacetate. Guanidoacetatete (CT6.2) then converts to creatine. Creatine (PT14.7) finally converts to creatinine (PT18.7) or sarcosine (PT18.0), which is also converted from dimethylglycine (PT16.5). The differences in the peak times of these metabolites may reflect successive processing throughout the day in the creatine pathway and neighboring glycine and threonine metabolism ( Fig. S4 ).
Our results suggest that metabolite-timetable method can detect circadian rhythm disorders in vivo. In a normal situation, patients live under the zeitgeber (e.g., light). Notably, our method successfully diagnoses the jet-lag state under LD conditions ( Fig. 5 and Fig.  S2 ), and this strongly suggests that endogenous abnormal clock state can be diagnosed by our method, even if there is external time information such as light. Circadian rhythm disorders are caused by environmental factors (such as jet lag) and/or inherited factors (as in familial advanced sleep-phase syndrome). Brown et al. (44, 45) reported detecting circadian rhythm disorders by characterizing the feature of molecular circadian clocks in the isolated cells. They collected skin samples from human subjects, cultured the cells, and transfected clock-controlled reporter into the cells. The features of the molecular circadian clock in the isolated cells correlated with the chronotypes (i.e., the feature of organismal circadian clock) of the subjects, suggesting that the method should also allow detection of inherited circadian rhythm disorders. Our method can detect both inherited and acquired circadian rhythm disorders but cannot distinguish between them, whereas Brown et al.'s (44, 45) method can detect inherited but not acquired disorders. These 2 methods are therefore complementary for detecting circadian rhythm disorders.
Although our results suggest the metabolite-timetable method can successfully estimate BT, keeping MS and hiring a specialized operator in each hospital seems difficult. Establishing a special center for ''detecting BT'' performing MS analysis is 1 possibility to solve this. Another possibility is detecting time-indicating metabolites in a specific way (e.g., making an ELISA kit for detecting BT using a specific antibody for target time-indicating metabolites). To achieve the latter possibility, the assignment of oscillatory peaks to known metabolites is important, and we already identified 14 (LC-MS) and 28 (CE-MS) oscillatory peaks as known metabolites (Figs. 1 and S3). We also examined the effect of peak numbers on BT estimation. Fig. S5 shows the accuracy of the BT estimation using the different number of oscillatory metabolites. If we set the statistical error rate P Ͻ 0.05 and estimation error between environmental and estimated time Ͻ2 h, the minimum number of time-indicating metabolites was Ϸ20. In addition, the effect of feeding is an important issue, especially in humans, because humans eat different amounts of food at entirely different times. Further analysis on food intake conditions would be a great help for applying this method in clinical situations.
In this study, we showed that a metabolite-timetable method based on LC-MS analysis is able to estimate individuals' BTs with a high degree of accuracy throughout the time of the day, under different lighting conditions (LD and DD), and in individuals with different genetic backgrounds (CBA/N and C57BL/6 mice) (Figs. 2 and 3). We also found that the LC-MS-derived metabolite timetable is robust despite differences in age, sex, and feeding ( Fig. 4 ); in addition, it is a sensitive and accurate detector of disordered circadian rhythm in jet-lagged mice. Our preliminary results suggest that the metabolite-timetable method can be also applied to other metabolomics techniques such as CE-MS; it allowed quantification of hundreds of clock-controlled metabolites, of which many could be identified, enabling successful measurement of BT from independent blood samples. The next step is to construct a metabolite timetable for human blood plasma, which will help measurement of BTs for humans and diagnosis of circadian rhythm disorders and facilitate the development of chronotherapy and tailored medication regimens.
Materials and Methods
BT Measurement. Metabolomics-based measurement of BT is performed as described for expression-based measurement of BT (16) , except that 2 samples are used for an estimation of BT. In the metabolite-timetable method, we used 2 samples with 12-h sampling time interval (e.g., ZT0 and ZT12 are used for 1 measurement of BT) to calibrate measurement-to-measurement experimental fluctuations of detection sensitivity, which usually differs among metabolites. We define the area in a certain sample as A si and the mean areas of 2 samples (of 12-h time interval) as M si for metabolite i. We also define the mean, standard deviation, and peak time of metabolite i in the timetable as M ti, Sti, and pti, respectively. For estimation of BT, we did not use outlying metabolites that do not satisfy the condition (͉(M ti Ϫ Msi)/Sti͉ Ͻ 2 ͌ 2). By changing b to 0, 0.1, . . . , 23.9, we searched for b with a maximum Pearson's correlation between { ͌ 2 cos(2(Pti Ϫb)/24)} and {(Asi Ϫ Msi)/Sti}, and we predicted b as BT of the target sample. To estimate the P value of the prediction, we applied a permutation test to the maximum correlations.
Ethics.
All experiments were performed with the permission of Kobe Animal Experiment Supervisory Panel (permission IDs are AH15-10 and AH18-01). 
Supporting Information. More Materials and Methods information is available in
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SI Text
CE-MS-Based Metabolite-Timetable Method with
More Stringent Criterion. As described in the main text, CE-MS analysis detected 953 peaks from blood plasma samples. Among these peaks, 44 peaks exhibit significant circadian oscillations under more stringent oscillation criterion (FDR Ͻ0.01, Fig. S3E ). Ten peaks, corresponding to 22.7% of these peaks of circadian oscillations, were identified as known metabolites (Fig. S3F ). Based on these detected and/or identified time-indicating metabolites by CE-MS analysis, we can construct the metabolite timetable in mice blood plasma (see Table S3 ).
To verify the possibility that this metabolite timetable well represent BT of individuals, we attempted to estimate the BT from the metabolite profiles of independently sampled mice. We assessed the metabolite profiles of fresh blood plasma from individual young male CBA/N mice every 4 h over 24 h both under LD or DD conditions ( Fig. S3 G and H) . As expected, we can significantly detect circadian rhythmicity in all metabolite profiles of these samples (P Ͻ 0.01, Fig. S3 G and H). The estimated BT closely matched with the sampling time with the estimation errors, 1.5 Ϯ 0.76 h for LD condition and 1.4 Ϯ 0.90 h for DD condition (mean Ϯ SD). These results suggest that the CE-MS -based method, with the time-indicating metabolites selected by the same stringent criterion (FDR Ͻ 0.01) as the LC-MS-based method, can accurately detect the internal BT of independently sampled individuals (Table S4) .
Possible Mechanisms to Generate Circadian Oscillations of Metabo-
lites. In this study, we found many oscillatory metabolites in mice blood by LC-MS (176 peaks for negative ions and 142 peaks for positive ions) and by CE-MS (153 peaks for positive ions). There are possible mechanisms to generate circadian oscillations of metabolites. The first possible mechanism is the regulation of the physiological input (e.g., food intake) and output (e.g., behavioral activity) by circadian clock. Through these regulations, the metabolites are rhythmically supplied, and/or rhythmically consumed in the body. The second possibility is the direct regulation of the key regulatory enzymes of the target metabolic pathways by circadian clock. For example, circadian clock system can regulate transcription of key enzymes via clock-controlled elements including E-box, DBP-binding element (D-box) and Reverb/ROR binding element (RRE) (1, 2) . Posttranscriptional regulation of these enzymes may be included in this possibility. The third possibility would be more indirect/additional effects on the metabolism by the circadian clock. Circadian clock controls many physiological phenomena like hormonal secretions. For example, secreted hormones can also regulate endogenous metabolites state rhythmically.
The Possible Tissue Sources of the Circadian Oscillations of Blood Metabolites and the Possible Mechanisms to Generate the Biased
Distribution of Their Phase. Strictly speaking, there is no single internal body time because different tissues have different internal time with phase differences. Therefore, it is worthwhile to discuss about the possible tissue sources to generate the circadian rhythmicity of metabolites in blood. As we discussed in the main text, we found in LC-MS analysis that lysophsophatidylcoline exhibited significant circadian oscillations in mice blood, which might be generated by circadian oscillations of a key enzyme synthesizing lysophosphatidylcoline, Lipc (hepatic lipase) in the liver (3) . We note that Lipc mRNA are rhythmically expressed in the mouse liver with the peak time around PT5 (3), which slightly proceeds with the peak time of identified oscillatory lysophosphatidylcolines (PT 5.8-PT 9.1). In CE-MS analysis, we found that metabolites in urea cycle exhibit circadian oscillations. Urea generation is one of the main functions in liver. We note that mRNA of Asl, which represents the gene for key enzyme involved in urea generation, is rhythmically expressed in the mouse liver with the peak time around PT18 (3). Reddy et al. (4) reported that protein levels of CPS1, ASS1, and ARG1 show circadian rhythmicity. ASS1 converts citrulline to argininosuccinate and the CPS acts as the rate-limiting step in ureagenesis by converting ammonia to carbamoyl phosphate. According to their data, ASS1 and CPS peaked during circadian night when nocturnal feeding and digestion would present amino acids to the hepatocytes, whereas ARG1, the final stage before urea production, peaked later in circadian day, when digestion would have been complete (4) . According to these results, the contribution of the liver seems important for generating circadian oscillations of the blood metabolites. We also note that observed distribution of peak time of blood metabolites converges into 2 phases (i.e., around midday and around midnight). This might be because specific metabolic pathways are controlled by circadian clocks. Actually, as we discussed in the above, the identified metabolites in LC-MS and CE-MS are involved in a few specific pathways such as lysophosphatidylcoline pathway peaking around midday (Fig. 1) , and urea cycles and glycinethreonine metabolism peaking around midnight ( Fig. S4B ). Further assignment of the oscillatory peaks to known metabolites should contribute to unveil the mechanism to generate circadian oscillations of blood metabolites and the biased distribution of their phase.
Why We Focused on Cosine-Wave-Like Metabolites. In this study, we focused on cosine-wave-like metabolites by fitting time-course data of blood metabolite concentrations to cosine wave (SI Materials and Methods). This is because the estimation of peak time of circadian metabolites of cosine-wave form is not affected by the time points in the construction of molecular timetable (if these are of 4-h time intervals). We also note that we calculated a continuous peak time of each oscillatory metabolite from the wave-form of its time-course data. Theoretically speaking, the calculated (continuous) peak time of metabolites doe not depend on the time points in the construction of molecular timetable when we focus on the cosine-wave-like metabolite as we did in this study. Therefore, even if the test samples are collected at any time points in-between these time points, it doesn't affect the estimation of body time.
Because we focused only on cosine-wave-like metabolites, we might miss circadian metabolites of noncosine wave form in this study. To find such noncosine-wave-like metabolites, another type of statistical filter will be helpful. For example, the ANOVA test with periodicity test like autocorrelation is 1 possibility. In addition, a more narrow time window (i.e., 1 or 2 h) and/or more long-term (e.g., 3 or 4 days) sampling might be also helpful.
SI Materials and Method
Animals. CBA/N mice were purchased from Japan SLC. Young male or female mice were 5-6 weeks old, and aged male mice were ''retired breeders'', aged Ϸ6 months. Male C57BL/6 mice (5-6 weeks old) were purchased from Charles River. All mice were kept under light-dark (LD; light 12 h, dark 12 h) conditions over 2 weeks with food pellets (CRF-1, Charles River) and water given ad libitum. Cry1Ϫ/Ϫ and Cry2Ϫ/Ϫ mice were originally generated by A.Y. and G.T.J.v.d.H, and the founder population was transported from Tohoku University to RIKEN CDB, where they were maintained and reproduced.
Sampling Schedule. Sampling of mouse plasma was performed under both LD and DD conditions. For DD sampling, the housing condition was changed to constant darkness on the day that sampling began. Sampling was started at ZT0/CT0. Trunk body blood was collected in tubes containing Novoheparin (Mochida Pharm) every 4 h for 2 days (12 samples in total).
Fasted mice were food deprived by removing food pellets from their cages at the light-off point 1 day before sampling began. They were deprived of food until their trunk blood was collected. Sampling began at ZT4 (4 h after light on) and ended at ZT0 the next day (6 time points). Immediately before they were killed, they were weighed to determine how much weight they had lost. To extract the plasma, blood was centrifuged twice at 1,000 ϫ g for 5 min at 4°C. Supernatants were withdrawn and stored at Ϫ80°C in a deep-freezer until RIA or metabolome analysis was performed.
Jet-Lag Experiment. Young male CBA/N mice were maintained under LD cycles (light 12 h, dark 12 h) for 2 weeks. Then the lighting schedule was shifted by 8 h (day 1). The mice were killed, and trunk blood was collected on days 1, 5, and 14. Their behavior was monitored by an infrared monitoring system (NS-AS01, Neuroscience) and data were visualized with Clock-Lab software (Actimetrix).
Corticosterone RIA. [1, 2, 6, H(N)]-Corticosterone (NET-399, 2.6 TBq/mmol) and the rabbit anticorticosterone serum (FKA-420) were obtained from PerkinElmer Japan and Cosmo Bio, respectively. After the addition of 200 l of the assay buffer (Gel-PBS; 20 mM phosphate buffer containing 0.1% gelatin and 140 mM NaCl), plasma samples (5 l) were extracted with diethylether (1 ml for 2 times). The organic phase was separated from the aqueous phase and evaporated with a vacuum evaporator. The residue was dissolved in 250 microliters of Gel-PBS and 50microliter aliquots were subjected to RIA. A standard curve (6.25-800 pg/tube) was constructed by using serial 2-fold dilutions of authentic corticosterone (Sigma) dissolved in Gel-PBS. For the initiation of RIA, anticorticosterone serum (1:10,000 dilution with PBS containing 50 mM EDTA, 100 l) and [1,2,6,7-3 H(N)]-corticosterone (Ϸ10,000 dpm in Gel-PBS, 100 l) were added to test tubes containing Gel-PBS and the standard or samples (200 l in total). After incubation for 24 h at 4°C, dextran-coated charcoal solution (200 L; Norit SX-3, 0.5 g/L, Wako Pure Chemicals, and 0.05 g/L dextran T-70, Amersham Pharmacia, in 20 mM phosphate buffer containing 140 mM NaCl, 50 mM EDTA, and 0.1% sodium azide, pH 7.5; EDTA-PBS) and incubated for 15 min at 4°C until centrifugation (2,000 ϫ g) for 15 min at 4°C. The supernatant was decanted into a scintillation vial (Pony Vial, PerkinElmer Japan) containing 2 mL of scintillant (Clearsol-1, Nakalai Tesque). The tube was capped and mixed, and then the radioactivity was counted in a liquid scintillation counter (Aloka). Parallelism of inhibition curves was proved between serial 2-fold dilution of corticosterone standard and the plasma extract (data not shown). Intraand interassay coefficients of variation were 7.3% (n ϭ 10) and 8.4% (n ϭ 16) at the 500 pg/tube level, respectively. The minimum detectable level defined as 2 standard deviations from the buffer control was Ͻ62.5 pg/tube. Cross-reactivities of the antiserum according to the manufacturer were as follows: deoxycorticosterone, 4.80%; 11-dehydrocorticosterone, 4.70%; progesterone 5.40%; cortisol, 2.20%; 4-androstenedione, 1.20%; cortisone, 0.23%; 17-hydroxy-11-deoxycorticosterone, 0.19%; 17alpha-hydroxyprogesterone, 0.30%; testosterone, 0.35%; al-dosterone, pregnenolone, 17alpha-hydroxy-prognenolone, dehydroepiandrosterone, and estradiol-17beta, Ͻ0.01%. LC-MS Samples. After acetonitrile (225 L) was added, plasma samples were shaken and centrifuged. Supernatants were placed in new tubes and dried. Acetonitrile (25 L) was added to the samples before analyzing the metabolites.
LC-MS Conditions. The LC system used was an Agilent 1100 series HPLC (Agilent Technologies). The ZORBAX SB-C18 RRHT (2.1 50 mm, 1.8 m) was purchased from Agilent Technologies, and columns were kept at 60°C. The mobile phase consisted of 0.1% acetic acid/water as A and methanol as B. The gradient went from 40% B in 0 min, 99% in 20 min, 99% in 30 min, 40% in 30.01 min, and then kept at 40% B until 40 min. The flow rate was 0.2 mL/min, and the injection volume was 1 L. MS data were acquired on a Qstar XL mass spectrometry (Applied Biosystems). Samples were analyzed by both positive and negative ion electrospray mass spectrometry. The MS conditions for positive ions (positive, TOF scan mode) were as follows: spray voltage, 5.5 kilovolts; scan range m/z 250-700; curtain gas, 20 arbitrary units (nitrogen); gas 1, 50 arbitrary unit; gas 2, 50 arbitrary units (500°C). Declustering potential 1/2 was 50 volts/15 volts. The MS conditions for negative ions (negative ion mode, TOF scan) was almost of the same as positive ion conditions, but the spray voltage was Ϫ4.5 kilovolts and declustering potential 1/2 was Ϫ50 volts/Ϫ15 volts.
LC-MS/MS Conditions.
We performed LC-MS/MS for associating oscillatory peaks to known chemicals as described in the previous report (5) with little modified. The LC system used was an Agilent 1100 series HPLC (Agilent Technologies) and the mobile phase consisted of 0.1% acetic acid/water as A and methanol as B. MS data were acquired on a Qstar XL mass spectrometry (Applied Biosystems).
CE-MS Samples.
To select oscillatory substances, pooled mouse plasma (4-10 mice per time point) was used; individual mouse plasma was used for BT measurement. Plasma samples (100 L) were plunged into 1.8 mL of methanol containing 55 M each methionine sulfone and 2-Morpholinoethanesulfonic acid (Mes) and mixed well. Then 800 L of deionized water and 2 mL of chloroform were added, and the solution was centrifuged at 2,500 ϫ g for 5 min at 4°C. The 800-L upper aqueous layer was centrifugally filtered through a Millipore 5-kDa cutoff filter to remove proteins. The filtrate was lyophilized and dissolved in 50 L of Milli-Q water containing reference compounds (200 M each of 3-aminopyrrolidine and trimesate) before CE-TOFMS analysis.
Metabolite Standards for CE-MS. All chemical standards were obtained from common commercial sources and dissolved in Milli-Q (Millipore) water, 0.1 N HCl or 0.1 N NaOH to obtain 10 or 100 mM stock solutions. Working standard mixtures were prepared by diluting stock solutions with Milli-Q water immediately before injection into the CE-TOFMS. The chemicals used were of analytical or reagent grade.
Instrumentation for CE-MS. All CE-TOFMS experiments were performed using an Agilent CE capillary electrophoresis system (Agilent Technologies), an Agilent G3250AA LC/MSD TOF system (Agilent Technologies), an Agilent1100 series binary HPLC pump, and the G1603A Agilent CE-MS adapter and G1607A Agilent CE-ESI-MS sprayer kit. For system control and data acquisition, we used the G2201AA Agilent ChemStation software for CE and the Analyst QS for Agilent TOFMS software. CE-MS/MS analyses for compound identification were performed on a Q-Star XL Hybrid LC-MS/MS System (Applied Biosystems) connected to an Agilent CE instrument.
CE-TOFMS Conditions for Cationic Metabolite Analysis.
Separations were carried out in a fused silica capillary (50-m inner diameter ϫ 100-cm total length) filled with 1 M formic acid as the electrolyte (6) . ϫ48 Ϸ3 nL of the sample solution was injected at 50 mbar for 3 s and 30 kilovolts of voltage applied. The capillary temperature was maintained at 20°C, and the sample tray was cooled below 5°C. Methanol water (50% vol/vol) containing 0.5 M reserpine was delivered as the sheath liquid at 10 L/min. ESI-TOFMS was operated in the positive ion mode, and the capillary voltage was set at 4 kilovolts. A flow rate of heated dry nitrogen gas (heater temperature 300°C) was maintained at 10 psig. In TOFMS, the fragmentor, skimmer and Oct RFV voltages were set at 120, 50, and 200 volts, respectively. Automatic recalibration of each acquired spectrum was performed using reference masses of reference standards. There are longer intervals between the measuring dates of 3 series (Ϸ3 months between the first and the second series and Ϸ1 year between the first and the third series).
For the intraseries peak association, we used Marker View software (Applied Biosystems). We set the detection range of the migration time from 3 to 28 min. For the interseries peak association, we first corrected retention time (RT) according to the reported method (7), then we associated the peaks in 2 series with the smallest values of:
(difference of m/z between 2 series/X) 2 ϩ (difference of RT between 2 series/Y) 2 in peaks with (difference of m/z) Ͻ X and (difference of RT) Ͻ Y in both series. Parameters X and Y were determined by the following procedure: (i) the values of X and Y were changed (e.g., X ϭ 0.01, 0.02, .., 0.15 and Y ϭ 0.1, 0.2, .., 1.5) and peaks were associated. (ii) Pearson's correlations of the associated peak area were calculated, and P values were estimated. (iii) We then chose the parameter sets with the smallest P values. In this procedure, the best parameter sets were X ϭ 0.09, Y ϭ 0.5 (positive ions), and X ϭ 0.13, Y ϭ 0.4 (negative ions) for the first and the second series and X ϭ 0.11, Y ϭ 0.9 (positive ions) and X ϭ 0.15, Y ϭ 1.3 (negative ions) for the first and the third series.
Associating Peaks of CE؊MS Data. We associated peaks of CE-MS data with the KEIO MasterHANDs software (8) , in which automated algorithm and manual curation are used. Making the Metabolite Timetable. First, we chose substances that were detected at 10 or more time points in both LD and DD conditions. Next, for each chosen metabolite, area values in LD and DD were scaled to have the same mean values in LD and DD. For the scaled areas, we searched for the maximum Pearson's correlation of a cosine curve over a 24-h period and its phase with a Fourier transformation-based method (9) . We then estimated P values and FDRs by permutation tests. Substances that have FDR Ͻ0.01 for LC-MS data and both FDR Ͻ0.01 and FDR Ͻ0.1 for CE-MS data were selected as significantly oscillating metabolites. We focused on cosine-wave-like metabolites, because the estimation of peak time of circadian metabolites of cosine-wave form is not affected by the time points in the construction of metabolite timetable.
Metabolic Map. Identified circadian oscillatory metabolites were put on the known metabolic map, and the metabolic map was generated through the use of Ingenuity Pathways Analysis (ver. 7.0, Ingenuity Systems).
Estimating a Lower Bound of Peak Counts in a Reliable Timetable.
To estimate a lower limitation of the number of peaks in a timetable, we performed BT estimation algorithm with shrunk timetables. For choosing n peaks in a timetable, all positive and negative ion peaks were sorted by P value (FDR) of their circadian oscillation and by correlations to cosine curves within the same P values, and the best n peaks were retrieved. By changing the number of peaks (n) within a range between 3 and 200, BTs of LD and DD individual samples were estimated with the shrunk timetables, and mean estimation errors and P values were calculated. (Table S1 ). The red cosine curve is the estimation, the blue curve is the environmental time (pre-LD condition shift), and the brown cosine curve is the environmental time (postshift). See also Table S2 for statistics. (Table S3 ). Peak time of the red cosine curves indicates estimated BT, and peak times of the blue indicate the environmental time. The dashed vertical lines show the BT (red) or environmental time (ZT/CT, blue). See Table S4 for statistics. The ЉNameЉ column indicate the name of the substance if found. The ЉAverage m/zЉ, ЉAverage MTЉ, ЉAverage area/area (IS1)Љ, ЉSD area/area (IS1)Љ columns indicate a mean m/z value, a mean retention time, a mean area and a standard deviation area divided by the area of an internal standard (methionine sulfone) of 24 time points (LD 12 time points ϩ DD 12 time points) for each associated peaks, respectively. ЉPeak timeЉ, ЉCorrelationЉ, ЉP valueЉ and ЉFDRЉ indicate the results of the statistical analysis of the circadian oscillation and represent a peak time of circadian oscillation, the maximum Pearson's correlation to a fitted cosine curve, P value and FDR estimations of its significance, respectively. P values and FDRs were rounded up and the other values were rounded off. All 153 peaks information was used to estimate BT (FDR Ͻ 0.1, Fig. S3 A-D) . For BT estimation using much severer condition (FDR Ͻ 0.01), 44 peaks information (no.1-4) was used ( Fig. S3 E-H). The ЉPeakЉ indicates as used peaks number (ЉUsedЉ) over associated oscillatory peaks in the samples (ЉAllЉ). ЉZT/CTЉ indicates environmental time in ZT (LD conditions) or CT (DD conditions) when the sample was taken. The ЉDifferenceЉ is determined as follows: BT -(environmental time). See Table S3 for used oscillatory peaks information (metabolite timetable). See also Materials and Methods for details. LD; light-dark, DD; constant dark, ZT; zeitgeber time, CT; circadian time.
